Effectiveness and safety of 17β-estradiol / drospirenon для менопаузальной гормональной терапии у пациенток с риском развития метаболического синдрома

Abstract

Objective: study of effectiveness and safety of indication of a combination 17β-estradiol/drospirenon in patients with various manifestations of the climacteric syndrome and risk of the metabolic syndrome development.Materials and methods. Results of two-year therapy of climacteric syndrome by 17β-estradiol/drospirenon drug in 21 patient in post-menopause.Results. As a result of two-year administration of the 17β-estradiol/drospirenon drug in patients with a risk of metabolic syndrome development a significant reduction of Kuppermann index was observed as well as improvement of the skin and mucous tunic state. No negative effect of the drug on lipid exchange values and homeostasis parameters, arterial pressure value, growth of myomatous nodules and thickness of endometrium.Conclusions. A combination of 17β-estradiol/drospirenon is effective and safe in therapy of climacteric disturbances and might be a drug of choice for patients with a risk of metabolic syndrome development.

Keywords

• 17β-estradiol/drospirenon
• post-menopause
• metabolic syndrome